August 13, 2024

Sens. Eliz­a­beth War­ren (D-MA) and An­gus King (I-ME), and Rep. Lloyd Doggett (D-TX) are once again urg­ing the fed­er­al gov­ern­ment to “im­me­di­ate­ly strength­en and fi­nal­ize

Re­vance Ther­a­peu­tics, the mak­er of Botox com­peti­tor Daxxi­fy, will be ac­quired for more than $900 mil­lion. Crown Lab­o­ra­to­ries will buy out … Sign up to

No­vo Nordisk, with da­ta on-hand from a late-stage tri­al of IcoSe­ma, is prepar­ing for an FDA fil­ing in type 2 di­a­betes slat­ed for the sec­ond

Three ar­ti­cles de­tail­ing the mid-stage tri­al re­sults of Lykos Ther­a­peu­tics’ MD­MA-as­sist­ed ther­a­py were re­tract­ed by the med­ical jour­nal that pub­lished them, cit­ing a fail­ure by

Plus, news about scPhar­ma­ceu­ti­cals and BiVic­triX: Tenax Ther­a­peu­tics’ $100 mil­lion PIPE: The com­pa­ny plans to put the mon­ey to­ward a sec­ond … Sign up to

As­cendis Phar­ma an­nounced Mon­day that it won FDA ap­proval for its hy­poparathy­roidism drug, of­fer­ing the small com­mu­ni­ty of those suf­fer­ing from in­suf­fi­cient lev­els of parathy­roid